S194: TECLISTAMAB (TEC) + NIROGACESTAT (NIRO) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): THE PHASE 1B MAJESTEC-2 STUDY

Bibliographic Details
Main Authors: Fritz Offner, Olivier Decaux, Cyrille Hulin, Sébastien Anguille, Anne Sophie Michallet, Luciano Costa, Cyrille Touzeau, Kevin Boyd, Deeksha Vishwamitra, Yue Guo, Zhuolu Niu, Julie Larsen, Lingling Chen, Arnob Banerjee, Jenna Goldberg, Jeffrey Matous
Format: Article
Language:English
Published: Wiley 2023-08-01
Series:HemaSphere
Online Access:http://journals.lww.com/10.1097/01.HS9.0000967688.12579.64
_version_ 1827332468446855168
author Fritz Offner
Olivier Decaux
Cyrille Hulin
Sébastien Anguille
Anne Sophie Michallet
Luciano Costa
Cyrille Touzeau
Kevin Boyd
Deeksha Vishwamitra
Yue Guo
Zhuolu Niu
Julie Larsen
Lingling Chen
Arnob Banerjee
Jenna Goldberg
Jeffrey Matous
author_facet Fritz Offner
Olivier Decaux
Cyrille Hulin
Sébastien Anguille
Anne Sophie Michallet
Luciano Costa
Cyrille Touzeau
Kevin Boyd
Deeksha Vishwamitra
Yue Guo
Zhuolu Niu
Julie Larsen
Lingling Chen
Arnob Banerjee
Jenna Goldberg
Jeffrey Matous
author_sort Fritz Offner
collection DOAJ
first_indexed 2024-03-07T16:59:23Z
format Article
id doaj.art-d3a128ba2d614153859705738f388362
institution Directory Open Access Journal
issn 2572-9241
language English
last_indexed 2024-03-07T16:59:23Z
publishDate 2023-08-01
publisher Wiley
record_format Article
series HemaSphere
spelling doaj.art-d3a128ba2d614153859705738f3883622024-03-03T03:25:45ZengWileyHemaSphere2572-92412023-08-017e125796410.1097/01.HS9.0000967688.12579.64202308003-00096S194: TECLISTAMAB (TEC) + NIROGACESTAT (NIRO) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): THE PHASE 1B MAJESTEC-2 STUDYFritz Offner0Olivier Decaux1Cyrille Hulin2Sébastien Anguille3Anne Sophie Michallet4Luciano Costa5Cyrille Touzeau6Kevin Boyd7Deeksha Vishwamitra8Yue Guo9Zhuolu Niu10Julie Larsen11Lingling Chen12Arnob Banerjee13Jenna Goldberg14Jeffrey Matous151 University Hospital Ghent, Ghent, Belgium2 Centre Hospitalier Universitaire de Rennes, Rennes, France3 Hôpital Haut Leveque, University Hospital, Pessac, France4 Vaccine and Infectious Disease Institute, University of Antwerp and the Center for Cell Therapy and Regenerative Medicine, Antwerp University Hospital, Edegem, Belgium5 Centre Hospitalier Lyon Sud, Hospices Civils, Pierre Bénite, France6 University of Alabama at Birmingham, Birmingham, United States7 Centre Hospitalier Universitaire de Nantes, Nantes, France8 The Royal Marsden Hospital, London, United Kingdom9 Janssen Research & Development, Spring House, United States9 Janssen Research & Development, Spring House, United States10 Janssen Research & Development, Shanghai, China11 Janssen Research & Development, Los Angeles, United States9 Janssen Research & Development, Spring House, United States9 Janssen Research & Development, Spring House, United States12 Janssen Research & Development, Raritan, United States13 Colorado Blood Cancer Institute and Sarah Cannon Research Institute, Denver, United Stateshttp://journals.lww.com/10.1097/01.HS9.0000967688.12579.64
spellingShingle Fritz Offner
Olivier Decaux
Cyrille Hulin
Sébastien Anguille
Anne Sophie Michallet
Luciano Costa
Cyrille Touzeau
Kevin Boyd
Deeksha Vishwamitra
Yue Guo
Zhuolu Niu
Julie Larsen
Lingling Chen
Arnob Banerjee
Jenna Goldberg
Jeffrey Matous
S194: TECLISTAMAB (TEC) + NIROGACESTAT (NIRO) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): THE PHASE 1B MAJESTEC-2 STUDY
HemaSphere
title S194: TECLISTAMAB (TEC) + NIROGACESTAT (NIRO) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): THE PHASE 1B MAJESTEC-2 STUDY
title_full S194: TECLISTAMAB (TEC) + NIROGACESTAT (NIRO) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): THE PHASE 1B MAJESTEC-2 STUDY
title_fullStr S194: TECLISTAMAB (TEC) + NIROGACESTAT (NIRO) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): THE PHASE 1B MAJESTEC-2 STUDY
title_full_unstemmed S194: TECLISTAMAB (TEC) + NIROGACESTAT (NIRO) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): THE PHASE 1B MAJESTEC-2 STUDY
title_short S194: TECLISTAMAB (TEC) + NIROGACESTAT (NIRO) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): THE PHASE 1B MAJESTEC-2 STUDY
title_sort s194 teclistamab tec nirogacestat niro in relapsed refractory multiple myeloma rrmm the phase 1b majestec 2 study
url http://journals.lww.com/10.1097/01.HS9.0000967688.12579.64
work_keys_str_mv AT fritzoffner s194teclistamabtecnirogacestatniroinrelapsedrefractorymultiplemyelomarrmmthephase1bmajestec2study
AT olivierdecaux s194teclistamabtecnirogacestatniroinrelapsedrefractorymultiplemyelomarrmmthephase1bmajestec2study
AT cyrillehulin s194teclistamabtecnirogacestatniroinrelapsedrefractorymultiplemyelomarrmmthephase1bmajestec2study
AT sebastienanguille s194teclistamabtecnirogacestatniroinrelapsedrefractorymultiplemyelomarrmmthephase1bmajestec2study
AT annesophiemichallet s194teclistamabtecnirogacestatniroinrelapsedrefractorymultiplemyelomarrmmthephase1bmajestec2study
AT lucianocosta s194teclistamabtecnirogacestatniroinrelapsedrefractorymultiplemyelomarrmmthephase1bmajestec2study
AT cyrilletouzeau s194teclistamabtecnirogacestatniroinrelapsedrefractorymultiplemyelomarrmmthephase1bmajestec2study
AT kevinboyd s194teclistamabtecnirogacestatniroinrelapsedrefractorymultiplemyelomarrmmthephase1bmajestec2study
AT deekshavishwamitra s194teclistamabtecnirogacestatniroinrelapsedrefractorymultiplemyelomarrmmthephase1bmajestec2study
AT yueguo s194teclistamabtecnirogacestatniroinrelapsedrefractorymultiplemyelomarrmmthephase1bmajestec2study
AT zhuoluniu s194teclistamabtecnirogacestatniroinrelapsedrefractorymultiplemyelomarrmmthephase1bmajestec2study
AT julielarsen s194teclistamabtecnirogacestatniroinrelapsedrefractorymultiplemyelomarrmmthephase1bmajestec2study
AT linglingchen s194teclistamabtecnirogacestatniroinrelapsedrefractorymultiplemyelomarrmmthephase1bmajestec2study
AT arnobbanerjee s194teclistamabtecnirogacestatniroinrelapsedrefractorymultiplemyelomarrmmthephase1bmajestec2study
AT jennagoldberg s194teclistamabtecnirogacestatniroinrelapsedrefractorymultiplemyelomarrmmthephase1bmajestec2study
AT jeffreymatous s194teclistamabtecnirogacestatniroinrelapsedrefractorymultiplemyelomarrmmthephase1bmajestec2study